GlaxoSmithKline

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

It's quarterly results time for GlaxoSmithKline PLC and chief executive Emma Walmsley is unlikely to escape the pressure from the usual activist investors. Alongside US hedge fund Elliott Management, the FTSE 100 pharma giant has a new vocal shareholder on its register, London-based Bluebell Capital Partners.

GlaxoSmithKline boss Emma Walmsley to remain key focus for activist investors on quarterly results

WARREN, N.J., Oct. 26, 2021 /PRNewswire/ -- GSK Consumer Healthcare's (LSE/NYSE: GSK) Theraflu brand today announced the launch of the Rest & Recover Fund to provide relief for those facing access barriers to sick time and raise awareness of the cultural stigma associated with taking a sick day.

Theraflu Launches the Rest & Recover Fund to Help More Americans Take a Sick Day When Needed

Glaxo's (GSK) newer respiratory and HIV drugs are likely to have driven third-quarter sales. Although sales of vaccines are likely to have recovered, the impact of the COVID-19 vaccine prioritization may have continued.

Glaxo (GSK) to Report Q3 Earnings: What's in the Cards?

Devon Energy

Enterprise Products Partners

And perhaps even more in share price appreciation.

Investing $100,000 in These 3 Dividend Stocks Could Give You Annual Income of $7,700

The recent consumer healthcare interest signals that GlaxoSmithKline Plc is undervalued. Price to sales and price to EBIT show a conservative 40% relative undervaluation.

GlaxoSmithKline: Buyout Interest Sheds More Light Into The Company's 40%+ Undervaluation

Drug consulting group Evaluate thinks GlaxoSmithKline PLC ( GSK , Financial) should consider making a run at Biohaven Pharmaceutical Holding Company Ltd. ( BHVN , Financial) after the latter recorded outstanding third-quarter sales of its oral migraine therapy, Nurtec ODT.

Glaxo Should Consider Buying a Headache (Company), Says Industry Consultant

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Is GlaxoSmithKline (GSK) Stock Undervalued Right Now?

Pressure is building again on GlaxoSmithKline Plc's management with reports today that several private equity firms are looking at a deal for its consumer business arm. According to Bloomberg, Advent International, CVC Capital Partners and KKR are the private equity firms evaluating the business while the wire also suggests Blackstone, Carlyle Group and Permira might also be interested in a deal around the £40bn mark.

GlaxoSmithKline consumer arm attracting private equity interest - report

The London-listed drugmaker is working to spin off its consumer healthcare business—a joint venture with Pfizer— and is preparing for a separate listing.

Glaxo Stock Jumps as Private-Equity Firms Reportedly Circle Consumer Unit

GlaxoSmithKline is "firmly on track" to spin off its consumer health business next year, the British drugmaker said on Tuesday, after Bloomberg News reported the unit could attract bids from private equity firms such as Advent, CVC and KKR.

GSK on track with consumer split as buyout report boosts shares

Agenus

But those wins probably won't be all that big.

2 Stocks Set to Win From the Historic Malaria Vaccine Approval

GlaxoSmithKline PLC is to sell its iconic London HQ and will move staff to new offices in Surrey as its presses ahead with the split of its consumer and pharmaceutical arms. The GlaxoSmithKline sign at the top of its HQ in Brentford is the first indication for Heathrow passengers arriving via the M4 that they are in London.

GlaxoSmithKline calls time on iconic London HQ as split moves ahead

GlaxoSmithKline on Monday laid out plans for a new, 120 million pound ($164 million) headquarters for its soon-to-be-independent consumer healthcare business and also said its remaining pharmaceuticals and vaccines staff will relocate.

GSK to cement split with two new headquarters

Another big step in preventing HIV and AIDS has been taken and GlaxoSmithKline is at the forefront.

Here's Why 2022 Could Be a Huge Year for GlaxoSmithKline

GlaxoSmithKline intends to spin-off its consumer healthcare unit in 2022. The case for separation is strong, with the consumer healthcare business now at scale and the pharma and vaccines units performing well.

GlaxoSmithKline: I'm Convinced By The Spin-Off Plan (And Valuation)

The World Health Organisation (WHO) has recommended the use of GlaxoSmithKline's malaria vaccine in children living in sub-Saharan Africa and other regions with moderate to high malaria transmission. In a statement, GSK welcomed the WHO recommendation, saying its RTS,S vaccine “is the first and only malaria vaccine to have been shown in pivotal long-term clinical trials to significantly reduce malaria in children”.

GSK gets WHO recommendation for roll-out of malaria vaccine

GlaxoSmithKline GSK, -0.55% said Wednesday that the World Health Organization has widely recommended use of its malaria vaccine in children in sub-Saharan Africa and other regions with moderate or high rates of malaria transmission. A combination of malaria antivirals and the vaccine can cut the risk of episodes, hospital admissions, and death by about 70%, compared to using only the antivirals.

WHO widely recommends GSK's malaria vaccine

Glaxo (GSK) seeks approval for a new dispersible single-tablet regimen containing dolutegravir to treat children living with HIV.

Glaxo (GSK) Eyes Nod for Triumeq Expanded Use in Pediatric HIV

AbbVie

AstraZeneca

Bristol-Myers

Gilead Sciences

Johnson & Johnson

Eli Lilly

Pfizer

Sanofi

Large-cap pharmaceutical stocks offer investors stable, substantial dividends, regardless of market conditions. Here are nine that stand out.

9 Big Pharmaceutical Stocks Sporting Stellar Yields

There's plenty to like with this big pharma stock -- but a few problem spots, too.

Here's a High-Yield Dividend Stock Wall Street Thinks Could Jump 26% Within 12 Months

Merck

Merck KGaA (OTC: MKGAF) and GlaxoSmithKline Plc (NASDAQ: GSK) have ended their $4 billion collaboration on cancer treatment, bintrafusp alfa. Merck said the move was a mutual decision, primarily due to disappointing lung cancer trial data, adding that GSK made no milestone payments and no future milestone obligations remain.

GlaxoSmithKline, Merck KGaA End $4B Cancer Drug Pact

BioNTech SE

Kadmon Hlds

Novo Nordisk

Sanofi (SNY), Pfizer (PFE) and Novo Nordisk (NVO) are three large drugmakers that are worth betting on in the current scenario.

3 Big Drug/Biotech Stocks to Boost Your Portfolio's Health

DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced a mutual decision with GSK to terminate their agreement on bintrafusp alfa, effective September 30, 2021. The decision is based on the clinical trial data generated to date, most notably the previously reported results from the INTR@PID Lung 037 study, which did not replicate the encouraging data observed in earlier studies. Based on the data generated during the agreement, no milestone payment

Merck Announces Mutual Decision to End Bintrafusp Alfa Agreement With GSK

Glaxo's (GSK) HIV subsidiary, ViiV Healthcare gets FDA's priority review for a new drug application for long-acting cabotegravir regimen. ViiV Healthcare signs a deal for developing ultra long-acting HIV treatment.

Glaxo's (GSK) Long-Acting Drug NDA Gets Priority Tag for PrEP

ViiV Healthcare, a joint venture between GlaxoSmithKline plc (NYSE: GSK), Pfizer Inc (NYSE: PFE), and Shionogi,  presented three-year results from the TANGO study at IDWeek 2021. Phase 3 TANGO study assessed the antiviral efficacy and safety of switching to Dovato, a 2-drug regimen of dolutegravir/lamivudine in HIV-infected adults who are virologically suppressed stable on a tenofovir alafenamide fumarate (TAF)-based regimen.

News for GlaxoSmithKline Stock (GSK)